# A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors

> **NCT06610227** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **NING LI** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** SapRNA™-MICA/B Tumor Vaccine

## Key facts

- **NCT ID:** NCT06610227
- **Lead sponsor:** NING LI
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06610227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06610227, "A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06610227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*